Blood Cancers
3-Drug Carfilzomib Regimen Not Superior Than Standard of Care in Myeloma
BY JESSICA SKARZYNSKI
Intravenous Administration and Hepatitis
BY INSIGHTS FROM: AJAI CHARI, MD, MOUNT SINAI HEALTH SYSTEM; DANIEL VERINA, NP, MOUNT SINAI HEALTH SYSTEM
sNDA Submitted to the FDA for Earlier Selinexor Treatment in Myeloma
BY JASON M. BRODERICK
Cellular Therapies Boost Outcomes for Aggressive Lymphomas
BY BRIELLE BENYON
The Intravenous Administration of Monoclonal Antibodies
BY INSIGHTS FROM: AJAI CHARI, MD, MOUNT SINAI HEALTH SYSTEM; DANIEL VERINA, NP, MOUNT SINAI HEALTH SYSTEM
Hodgkin Lymphoma: PET Scans and New Therapies Move Field Forward
BY BRITTANY COTE
ICYMI: A Rundown of the 5 Latest FDA Approvals
BY BRIELLE BENYON
FDA Extends Review Period for Liso-Cel for Lymphoma Treatment
BY JASON M. BRODERICK
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.